Pioglitazone Intervention for Coronary Atherosclerosis in Patients with Metabolic Syndrome.

Pioglitazone Intervention for Coronary Atherosclerosis in Patients with Metabolic Syndrome. - PIGEON-MS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000332

Enrollment

100

Registered

2006-03-03

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerosis Metabolic syndrome

Interventions

Piogllitazone 30mg/day Valsartan 40-80mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Candidate for percutaneous coronary intervention LVEF > 40% Metabolic syndrome ()

Exclusion criteria

Exclusion criteria: Acute coronary syndrome (acute myocardial infarction / unstable angina) Undergo insulin therapy Severe liver dysfunction, severe renal dysfunction Undergo treatment of heart failure Already taking pioglitazone History of side effect of thiazolidines CD36 defficiency Pregnancy or possible pregnancy Non-hypertension

Design outcomes

Primary

Measure	Time frame
Change in volume of coronary atherosclerotic plaque evaluated by intravascular ultrasound Change in tissue components of coronary atherosclerotic plaque evaluated by intravascular ultrasound Change in plasma lipid profile Change in inflammatory markers	—

Secondary

Measure	Time frame
Death, Acute coronary syndrome, Newly onset of angina whose culprit lesion is subjective plaque, Severe heart failure	—

Countries

Japan

Contacts

Public ContactNobuyuki Komiyama

Saitama Medical University International Medical Center Cardiology

042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026